This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           January 07, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Random mutations may account for two-thirds of cancer risks
The New York Times
It may sound flippant to say that many cases of cancer are caused by bad luck, but that is what two scientists suggested in an article published last week in the journal Science. The bad luck comes in the form of random genetic mistakes, or mutations, that happen when healthy cells divide. Random mutations may account for two-thirds of the risk of getting many types of cancer, leaving the usual suspects — heredity and environmental factors — to account for only one-third, say the authors, Cristian Tomasetti and Dr. Bert Vogelstein, of Johns Hopkins University School of Medicine.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Late-breaking abstract submissions open until Feb. 5
SGO is accepting late-breaking abstract submissions for the Annual Meeting on Women’s Cancer® now through Feb. 5, 2015. This session will highlight data of the highest scientific impact that has become available since the original 2015 Annual Meeting abstract submission deadline on Sept. 17, 2014. Abstracts already submitted in response to the original Call for Abstracts for the 2015 Annual Meeting are not eligible for resubmission.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Neoadjuvant chemotherapy for ovarian cancer
OncLive
Current practice for the treatment of ovarian cancer involves primary de-bulking surgery followed by chemotherapy. Neoadjuvant chemotherapy, or the delivery of chemotherapy before surgery, tends to be used in patients who are not candidates for upfront de-bulking surgery, observes James Tate Thigpen, MD, and Robert A. Burger, MD.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Cytoreductive surgery for ovarian cancer
OncLive
Individuals with ovarian cancer who have been treated to the point of no visible residual disease have demonstrated better survival outcomes in clinical trials. Warner K. Huh, MD, acknowledges that although there is a risk of morbidity in pursuing this outcome, achieving zero-volume disease is the goal of surgery.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV


Evidence of effective delivery of the HPV vaccine through a publicly funded, school-based program
Medscape (Free login required)
Proper administration of the human papillomavirus (HPV) vaccine (three doses at 0, 2, and 6 months) will likely influence the vaccine's effectiveness and the impact of vaccination programs on health outcomes. BMC Public Health recently published a study in which researchers assessed HPV vaccine series completion and on-time dosing in Canada's largest publicly funded, school-based HPV vaccination program.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CURRENT PRACTICE




Are we ready for a paradigm shift in cancer investigation?
Clinical Oncology
Author Maurie Markman, MD, writes: At times it appears that a week does not go by without a report in a high-impact journal strongly suggesting that the “standard of care” for a cancer in a particular clinical setting must change based on the unique molecular biology in a subset of patients. Of course, any reported finding requires confirmation, and some have questioned the overall clinical impact of this ongoing evolution in the understanding of the role of “driver abnormalities” in individual cancers; however, the acceleration in the rate of discovery of useful (“actionable”) data that can be employed in routine cancer care is simply staggering.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Atypical hyperplasia linked to high lifetime risk of breast cancer
Medical News Today
Researchers have long known that atypical hyperplasia — an accumulation of abnormal cells in the ducts or lobules of the breast — can increase a woman's risk of breast cancer. But a new study by researchers from the Mayo Clinic finds that this risk may be higher than previously thought.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISS AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


Decreased fat intake may offer additional benefit for breast cancer survivors
Healio
Beverly Moy, MD, MPH, clinical director of the breast oncology program at the Massachusetts General Hospital Cancer Center and a HemOnc Today Editorial Board member, highlights results from the from the Women's Intervention Nutrition Study (WINS) which found that early-stage breast cancer patients who reduced their dietary fat intake for five years following a diagnosis had significantly reduced rates of all-cause mortality.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Dec. 17, 2014
Dec. 10, 2014
Mock 2
Mock 2






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063